Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
11.0 EUR
8.80 B EUR
64.34 B EUR
29.01 M
About ROCHE I
Sector
Industry
CEO
Thomas Schinecker
Website
Headquarters
Basel
Founded
1896
ISIN
CH0012032113
FIGI
BBG000BNGZT0
Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Roche vs. Novo Nordisk: Who will suffer the Weight Loss?Roche (ticker: ROG.SW) is losing ground on the stock due to the side effects of its new weight loss pill, CT-996, which is still in the testing phase. After a rally that boosted its shares 40% between May and September, the Swiss drugmaker has seen an 11% drop in its shares in September alone, inclu
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896
Roche: Ready for 120% Growth?We're trying something with Roche here, where we think that we are currently in Wave (5), having recently completed Wave (4). This assessment is better visualized on the daily chart. Hence, we should maintain the 61.8% level for this Wave 4. Anything below would statistically be too low, while above
Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here.
Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma.
There were only 3 pull backs greater than 30% in the history of the stock.
2002 ~ 2003: -45.33%
2006 ~ 2011: -52.40%
2014 ~ 2018: -30.24%
2022 ~ present: -44.89%
It is at the support z
Roche HoldingsThis is one of those companies you can't afford not to look into. Roche is one of the world's largest biotech companies and a global leader in pharmaceuticals and diagnostics. This leading position translates to strong market share, revenue, and profitability. The company operates across various seg
Long Term Weekly Trend holds for nowTrend started in 2012 held during the week. If the price accumulates at the current level and we breakout to the upside, I will watch the marked zones of interest and see how the price reacts.
If we breakout to the down side, I will look for interesting price levels and keep an eye on the trend est
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
CHGCY5317644
Roche Holdings, Inc. 2.607% 13-DEC-2051Yield to maturity
7.08%
Maturity date
Dec 13, 2051
CHGCY4184535
Roche Holdings, Inc. 4.0% 28-NOV-2044Yield to maturity
5.90%
Maturity date
Nov 28, 2044
CHGCY5766486
Roche Holdings, Inc. 5.218% 08-MAR-2054Yield to maturity
5.72%
Maturity date
Mar 8, 2054
CHGCY3666852
Genentech, Inc. 5.25% 15-JUL-2035Yield to maturity
5.48%
Maturity date
Jul 15, 2035
CHGCY5766485
Roche Holdings, Inc. 5.218% 08-MAR-2054Yield to maturity
5.36%
Maturity date
Mar 8, 2054
CHGCY5766483
Roche Holdings, Inc. 4.985% 08-MAR-2034Yield to maturity
5.19%
Maturity date
Mar 8, 2034
CHGCY5698672
Roche Holdings, Inc. FRN 13-NOV-2026Yield to maturity
5.18%
Maturity date
Nov 13, 2026
CHGCY5766481
Roche Holdings, Inc. 4.909% 08-MAR-2031Yield to maturity
5.09%
Maturity date
Mar 8, 2031
CHGCY5766484
Roche Holdings, Inc. 4.985% 08-MAR-2034Yield to maturity
5.04%
Maturity date
Mar 8, 2034
CHGCY5317198
Roche Holdings, Inc. 2.076% 13-DEC-2031Yield to maturity
4.98%
Maturity date
Dec 13, 2031
CHGCY5766479
Roche Holdings, Inc. 4.79% 08-MAR-2029Yield to maturity
4.97%
Maturity date
Mar 8, 2029
See all RHO bonds
Curated watchlists where RHO is featured.
Related stocks
Frequently Asked Questions
The current price of RHO is 297.6 EUR — it has decreased by −1.00% in the past 24 hours. Watch ROCHE HLDG AG INH. SF 1 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ROCHE HLDG AG INH. SF 1 stocks are traded under the ticker RHO.
RHO stock has fallen by −1.65% compared to the previous week, the month change is a 40.38% rise, over the last year ROCHE HLDG AG INH. SF 1 has showed a 40.38% increase.
We've gathered analysts' opinions on ROCHE HLDG AG INH. SF 1 future price: according to them, RHO price has a max estimate of 485.97 EUR and a min estimate of 235.49 EUR. Watch RHO chart and read a more detailed ROCHE HLDG AG INH. SF 1 stock forecast: see what analysts think of ROCHE HLDG AG INH. SF 1 and suggest that you do with its stocks.
RHO stock is 1.01% volatile and has beta coefficient of 1.22. Track ROCHE HLDG AG INH. SF 1 stock price on the chart and check out the list of the most volatile stocks — is ROCHE HLDG AG INH. SF 1 there?
Today ROCHE HLDG AG INH. SF 1 has the market capitalization of 235.69 B, it has increased by 3.16% over the last week.
Yes, you can track ROCHE HLDG AG INH. SF 1 financials in yearly and quarterly reports right on TradingView.
ROCHE HLDG AG INH. SF 1 is going to release the next earnings report on Jul 24, 2025. Keep track of upcoming events with our Earnings Calendar.
RHO earnings for the last half-year are 9.12 EUR per share, whereas the estimation was 8.94 EUR, resulting in a 1.98% surprise. The estimated earnings for the next half-year are 11.25 EUR per share. See more details about ROCHE HLDG AG INH. SF 1 earnings.
ROCHE HLDG AG INH. SF 1 revenue for the last half-year amounts to 32.60 B EUR, despite the estimated figure of 32.74 B EUR. In the next half-year revenue is expected to reach 33.44 B EUR.
RHO net income for the last half-year is 2.15 B EUR, while the previous report showed 6.50 B EUR of net income which accounts for −66.96% change. Track more ROCHE HLDG AG INH. SF 1 financial stats to get the full picture.
Yes, RHO dividends are paid annually. The last dividend per share was 10.17 EUR. As of today, Dividend Yield (TTM)% is 3.50%. Tracking ROCHE HLDG AG INH. SF 1 dividends might help you take more informed decisions.
ROCHE HLDG AG INH. SF 1 dividend yield was 3.58% in 2024, and payout ratio reached 93.40%. The year before the numbers were 3.67% and 66.71% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of May 10, 2025, the company has 103.25 K employees. See our rating of the largest employees — is ROCHE HLDG AG INH. SF 1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ROCHE HLDG AG INH. SF 1 EBITDA is 22.37 B EUR, and current EBITDA margin is 35.81%. See more stats in ROCHE HLDG AG INH. SF 1 financial statements.
Like other stocks, RHO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ROCHE HLDG AG INH. SF 1 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ROCHE HLDG AG INH. SF 1 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ROCHE HLDG AG INH. SF 1 stock shows the strong buy signal. See more of ROCHE HLDG AG INH. SF 1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.